More Details on Acoramidis' Benefit in ATTR Cardiomyopathy: ATTRibute-CM
Experts hope the drug is approved and acts as a competitor to an existing, and expensive, treatment for ATTR-CM.
Source: tctmd.com
Stay updated with breaking news from Creteil. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Experts hope the drug is approved and acts as a competitor to an existing, and expensive, treatment for ATTR-CM.
Pivotal trial 'suggests the tantalizing possibility of genuine clinical improvement'
Lead author of the ATTRibute-CM trial says it was "robustly positive," and shows "the tantalizing possibility of genuine clinical improvements" for this progressive and fatal condition.
The official site of Nonesuch Records
The official site of Nonesuch Records